BioLegend

BioLegend is a developer and manufacturer of antibodies and reagents used in biomedical research.

History

2021: PerkinElmer bought BioLegend for $5.25 billion

At the end of September 2021, PerkinElmer announced the completion of the acquisition of the developer and manufacturer of antibodies and reagents used in biomedical research - the company BioLegend for $5.25 billion.

Teams and technologies will BioLegend play a crucial role in the ability of our combined companies to provide scientists with new innovative solutions that contribute to the discovery and development of new therapeutic drugs. We also expect that BioLegend will significantly expand our leading portfolio of reagents, as we work together to innovate and develop science for our customers, "said PerkinElmer President and CEO Prahlad Singh in a press release.

PerkinElmer acquired BioLegend for $5.25 billion

PerkinElmer plans to use this acquisition to expand its bioscience franchise in fast-growing fields, including cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation, and bio-processing.

We are very excited to roll up our sleeves and work with our new colleagues from PerkinElmer to leverage our portfolios, employees and overall passion for innovation and science to accelerate the discovery and development of new therapeutic drugs. A broad PerkinElmer platform in the life sciences and a powerful global infrastructure will help BioLegend continue to expand our mission, allowing our customers to make legendary discoveries, "said BioLegend President and CEO Jin Lei.

PerkinElmer expects BioLegend to generate additional revenue of $380 million and adjusted earnings per share of 30 cents per share in FY2022. The deal will be the largest in PerkinElmer history and is expected to be completed by the end of 2021, subject to regulatory approval and other normal closing conditions.^[1]

Notes